Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 July 2021 | Story Lunga Luthuli | Photo Supplied
Fletcher Hiten, Chief Bioanalyst at FARMOVS, next to Aurora.

The Bioanalytical Services Division (BASD) at FARMOVS comprises a group of skilled and passionate scientists involved in the quantification of drugs, metabolites, and biomarkers in various biological matrices. One of their Analytical Science experts, Fletcher Hiten, explains what sets their team apart from the rest.

“Over the past 47 years, we have developed almost 600 validated assay methods. Most of these methods are for the analysis of ‘small’ molecules using chromatographic techniques such as LC-MS/MS, GC-MS, and HPLC, although LC-MS/MS is the technique of choice. New bioanalytical assays are continuously being development and validated in adherence to international regulatory guidelines set by the US-FDA and European Medicines Agency (EMA),” says Hiten.

“Recently, we decided to enhance our capabilities by recruiting exceptional talent. The newest member of the FARMOVS team is Aurora, a SCIEX Triple Quad™ 7500 LC-MS/MS mass analyser. Aurora is Latin for ‘dawn’: the beginning of a new era, especially one considered favourable. The SCIEX 7500 is currently marketed as the most sensitive triple quadrupole mass spectrometer available, allowing for sub-picogram/ml quantification. This means that Aurora will set FARMOVS apart from other clinical research organisations (CROs), creating an exciting and favourable landscape for clients to explore new partners in research.” 

Hiten stated: “If there was ever a time to move your next study to FARMOVS, it is now. To have Aurora on our team has many advantages, given that our clients can access unprecedented analytical sensitivity, which enables the quantification of pharmacokinetic (PK) profiles of drugs that have very low systemic absorption. These include predominantly local acting drugs, such as plasma concentrations of respiratory drugs (e.g., tiotropium and ipratropium), topically applied creams and ointments, and ophthalmology drops with ultra-sensitivity.”

“In addition, the quantification of drugs in low-volume matrices will also be exponentially enhanced, enabling the quantification of body fluids, where only a few microlitres can be collected, for example vaginal fluid, dried blood spots, cerebrospinal fluid, aqueous humour, synovial fluid, and epidermal micro-dialysis lysate – to name a few. The quantification of absorbed exogenous drugs into tissue, like vaginal biopsies and hair follicles, is also possible,” added Hiten. 

“And finally, multiple analyte analysis. In this case, the collected blood sample needs to be split into multiple aliquots for analysis, for example drug-drug interaction (DDI) studies with the Basel cocktail. The smaller sample volumes will allow more frequent sampling to be feasible and thus more accurate DDI interpretation,” Hiten explains.

“As a bio-analyst, one is seldom surprised. However, Aurora has already opened doors to new frontiers for our entire team and we cannot wait to do some more exploration,” says Hiten. 

To find out more about what Aurora and the FARMOVS team can do for your study, email business@farmovs.com

News Archive

Dr Chantel Swart the ‘Expert on Stage’
2013-06-04

 

Presents Extraordinary Findings at International Nanomedicine Conference.
Photo: Sonia Small
04 June 2013

Dr Chantel Swart, an alumnus of the Prestige Scholars Programme (PSP) from the Department of Microbial, Biochemical and Food Biotechnology, is an invited “Expert on Stage” at the 4th International Nanomedicine Conference to be held in Sydney, Australia from 1 – 3 July 2013.

She is to share the podium with world authorities in nanomedicine.

Dr Swart’s presentation, “A New Nanotechnology for Nanomedicine”, will convey findings that made international headlines. She is part of the nanotechnology group of Prof Lodewyk Kock that discovered gas bubbles inside cells when using Auger-architectomics, a nanotechnology they developed in 2010. This nanotechnology is used to track nanomedicine inside cancer cells in collaboration with the Mayo Clinic in the US.

The Kock Nanotechnology Group includes scholars from the departments of Microbial, Biochemical and Food Biotechnology, Physics, Chemistry, the Centre for Microscopy (all from the UFS) and South African Breweries. Their breakthrough is also showcased on the cover of all issues of 2013 FEMS Yeast Research, a leading journal in yeast research. BiotecVisions and Global Medical Discovery (GMD) both selected this work for worldwide promotion at the end of 2012.

Dr Swart’s future research will use this newly-developed nanotechnology to visualize and hence explore the exposed nano-world. This will include work on the architecture of cells and effects of various drugs on cell metabolism.

A virtual tour is available at: http://vimeo.com/user6296337/videos.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept